Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- AbbVie
- Study ID
- NCT04195698
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Upadacitinib — DRUGUpadacitinib will be administered oral as tablet
Study Details
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.
Key Dates
- Start date
- Jan 15, 2020
- Status verified
- Jan 2025
- Primary completion
- Sep 11, 2023
- Completion
- Sep 11, 2023
Study Design
- Enrollment
- 475 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: UpadacitinibParticipants will be administered with upadacitinib once daily (QD)
Primary Outcome Measure
Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: UPA/UPA arm: BL visit in Lead-In M16-046 to last dose in Long-Term Extension M19-850 (median time on follow-up is 536 days); DUPI/UPA arm: BL visit in Long-Term Extension M19-850 to last dose plus a 30-day follow-up (median time on follow-up is 399 days). ]
Locations (33)
Find similar trials in Little Rock, AR
Related Studies
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)Recruiting · Regeneron Pharmaceuticals · Boston, Massachusetts
- Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 PolymorphismRecruiting · Boston Children's Hospital · Boston, Massachusetts
- CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and EffectivenessEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic DermatitisPHASE4 · Recruiting · Northwestern University · Chicago, Illinois